Publicacions en col·laboració amb investigadors/es de Medical University of Silesia (14)

2019

  1. Clinical outcomes of state-of-the-art percutaneous coronary revascularisation in patients with three-vessel disease: Twoyear follow-up of the SYNTAX II study

    EuroIntervention, Vol. 15, Núm. 3, pp. E244-A252

  2. Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: A European Scleroderma Trials and Research (EUSTAR) analysis

    Annals of the Rheumatic Diseases, Vol. 78, Núm. 9, pp. 1242-1248

  3. Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the european scleroderma trials and research (eustar) cohort

    Annals of the Rheumatic Diseases, Vol. 78, Núm. 5, pp. 648-656

2018

  1. Effect of hydrolyzed infant formula vs conventional formula on risk of type 1 diabetes the TRIGR randomized clinical trial

    JAMA - Journal of the American Medical Association, Vol. 319, Núm. 1, pp. 38-48

2017

  1. Global position paper on cardiovascular regenerative medicine

    European Heart Journal

  2. Long-term survival of patients with CLL after allogeneic transplantation: A report from the European Society for Blood and Marrow Transplantation

    Bone Marrow Transplantation, Vol. 52, Núm. 3, pp. 372-380

  3. The consensus of the Task Force of the European Society of Cardiology concerning the clinical investigation of the use of autologous adult stem cells for the treatment of acute myocardial infarction and heart failure: Update 2016

    European Heart Journal, Vol. 38, Núm. 39, pp. 2930-2935

  4. The effect of intracoronary infusion of bone marrow-derived mononuclear cells on all-cause mortality in acute myocardial infarction: rationale and design of the BAMI trial

    European Journal of Heart Failure, Vol. 19, Núm. 11, pp. 1545-1550

2016

  1. Combined optical coherence tomography morphologic and fractional flow reserve hemodynamic assessment of non- culprit lesions to better predict adverse event outcomes in diabetes mellitus patients: COMBINE (OCT-FFR) prospective study. Rationale and design

    Cardiovascular Diabetology, Vol. 15, Núm. 1

2015

  1. Use of anticoagulants and antiplatelet agents in stable outpatients with coronary artery disease and atrial fibrillation. International CLARIFY registry

    PLoS ONE, Vol. 10, Núm. 4

2012

  1. Acute coronary syndromes: Considerations for improved acceptance and implementation of management guidelines

    Expert Review of Cardiovascular Therapy, Vol. 10, Núm. 4, pp. 489-503

2011

  1. The impact of patient and lesion complexity on clinical and angiographic outcomes after revascularization with zotarolimus- and everolimus-eluting stents: A substudy of the RESOLUTE all comers trial (a randomized comparison of a zotarolimus-eluting stent with an everolimus-eluting stent for percutaneous coronary intervention)

    Journal of the American College of Cardiology, Vol. 57, Núm. 22, pp. 2221-2232

2010

  1. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents

    New England Journal of Medicine, Vol. 363, Núm. 2, pp. 136-146

2008

  1. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial

    The Lancet, Vol. 372, Núm. 9641, pp. 807-816